Clinical trials: NK-LGL Leukemia
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01273766
- Testing
- deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Myelodysplastic Syndromes
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
The goal of this study is to see if there is a benefit to giving chemotherapy and then natural killer (NK) cells. The NK cells must come from a family member who shares half of the patients HLA proteins.
- Trial name
- NCT00526292
- Testing
- natural killer cell therapy, cyclophosphamide, fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma.
- Conditions
- Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT03113500
- Testing
- Brentuximab Vedotin, Cyclophosphamide, Doxorubicin
- Where
- 5 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- City of Hope Medical Center
Leukemia, Chronic Myelogenous Leukemia
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
The goal of this clinical research study is to learn if giving a kind of immune cell called natural killer (NK) cells after chemotherapy will improve the response to a stem cell transplant in patients with CML.
- Trial name
- NCT01390402
- Testing
- Fludarabine, Busulfan, NK cell infusion:
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
Background: Bone marrow stem cells, which are found in the bone marrow and blood stream, can be collected and transplanted to treat a variety of types of cancer in a process known as hematopoietic stem cell transplantation…
- Trial name
- NCT01287104
- Testing
- Natural Killer (NK) Cell Infusion, Stem Cell Infusion
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell and donor natural killer cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00450983
- Testing
- muromonab-CD3, natural killer cell therapy, fludarabine phosphate
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Plasma Cell Leukemia, Plasma Cell Myeloma
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies the side effects and best dose of umbilical cord blood-derived natural killer cells when given together with elotuzumab, lenalidomide, and high dose melphalan before autologous stem cell transplant and…
- Trial name
- NCT01729091
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Elotuzumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Natural Killer (NK) Cell Transplantation for AML
The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.
- Trial name
- NCT00187096
- Testing
- Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2, Natural Killer Cell Infusion, CliniMACS System
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02259348
- Testing
- Cyclophosphamide, Fludarabine, G-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
RATIONALE: An Opioid Titration Order Sheet that allows healthcare providers to adjust the dose and schedule of pain medication may help improve pain treatment for patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00666211
- Testing
- educational intervention, Titrated pain management, questionnaire administration
- Where
- 11 sites in United States
- Volunteers
- 98 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Acute Myelogenous Leukemia
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR
This is a phase II trial designed to test the safety and efficacy (complete response [CR]) of related donor HLA-haploidentical NK-cell based therapy for the treatment of acute myelogenous leukemia (AML).
- Trial name
- NCT03152526
- Testing
- Interventions
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Miltenyi Biotec B.V. & Co. KG
Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma
- Trial name
- NCT00082888
- Testing
- Laboratory Biomarker Analysis, Tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Anemia, Leukemia
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00416624
- Testing
- darbepoetin alfa, epoetin alfa, fatigue assessment and management
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- Mayo Clinic